Aspire-Lakewood Files DCS Financials: $208.9M Revenue, $37.1M Bargain Gain, Lakewood Fee Deal
ASBP has more than doubled off its 52-week low of $3.309.
Summary
Aspire-Lakewood's amended 8-K supplies DCS's audited and interim financials plus pro forma results for the $30M acquisition that closed August 6 — $208.9M of 2025 revenue, a $37.1M preliminary bargain purchase gain, and a Lakewood management deal carrying 15% of DCS equity.
Key Events · M&A and Partnerships · ASBP
-
DCS Financials Filed for $30M Deal
Audited DCS revenue was $208.9M in 2025 (net income $9.8M) and $205.4M in 2024 (net income $22.8M); H1 2026 revenue was $103.8M with a $0.7M net loss.
-
$37.1M Preliminary Bargain Purchase Gain
Estimated fair value of net assets acquired is $67.8M against ~$30M of consideration, producing a $37.1M non-cash bargain purchase gain; the allocation is preliminary and could change materially.
-
Lakewood Management and Equity Terms
Lakewood Capital gets a $500K closing fee, up to $200K expense reimbursement, an annual fee of 5% of Adjusted EBITDA capped at $1.0M, plus 15% of DCS equity (~$4.5M) vesting monthly over two years and a tranche-based put option.
-
Deal Funded With New Bank Debt
Consideration was $8.8M of cash plus $21.9M drawn on an Axos Bank credit facility; pro forma long-term debt rises to $31.8M.
Analysis · ASBP · Life Sciences
The amendment puts hard numbers on the DCS acquisition that closed August 6. Revenue at DCS reached $208.9M in 2025, yet net income was only $9.8M; in the first half of 2026 the business swung to a $0.7M net loss on $103.8M of revenue, leaving it roughly breakeven at the operating line and showing that 2025 profit leaned on $17.7M of other income. A $37.1M preliminary bargain purchase gain appears in the pro forma, meaning Aspire paid about $30M for net assets it values at roughly $67.8M; that gain is a one-time accounting item, not cash, and the allocation is explicitly preliminary. Details of the Lakewood Capital management agreement are also disclosed: a $500K closing fee, up to $200K of expenses, an annual fee of 5% of Adjusted EBITDA capped at $1.0M, and 15% of DCS equity (about $4.5M) vesting over two years plus a put option that can be settled in cash or stock. Because of that 15% stake, Aspire does not own all of DCS's economics, and the put is carried as a liability remeasured each period. Funding came from $8.8M of cash plus $21.9M drawn on an Axos Bank facility, so the deal added real leverage to a company with a ~$12M market cap.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1560 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ASBP was trading at $8.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $3.31 to $562.92. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.